Cancers are genetic diseases caused by gradually accumulated mutations.When genes regulating cell growth are mutated or damaged, cells lose control and proliferate endlessly, eventually leading to malignant tumors.The mechanisms of cancer are highly complex. Even in tumors from the same organ, treatment protocols and results may vary. Individualized treatment based on a personalized mutation profile assists the selection of most appropriate therapeutic strategy for the best clinical outcome, maximizing treatment efficacy, prolonging survival and improving quality of life.
Accurately identifying unique genetic variants in each solid tumor, these products provide the best clinical evidence for precise clinical treatment, molecular classification and disease remission and relapse monitoring. They also provide key information for scientific research discovery.
Tumor liquid biopsy products Circulating tumor DNA (ctDNA) is free DNA fragment released from tumor tissue into the bloodstream. These fragments take tumor-specific genetic changes. Therefore, through non-invasive "liquid biopsy, ctDNA fragments in the blood of the cancer patients can be enriched to conduct molecular testing, which can help interpret the tumor molecular state of patients at any time. CtDNA,as a new type of tumor markers, helps to realize companion diagnostics,medicine guidance and efficacy monitoring by detection of ctDNA and the mutations associated with tumorigenesis and targeted drug information.
CanGermline,tumor-related genetic susceptibility testing products.CanGermline refers from dozens of international authoritative genome database(including China) and integrates 5000+ articles of scientific research results to provide more accurate information for clinical genetic syndrome screening and risk management. Once testing information is effective for life-time, and testing genetic counseling and the testing analysis are provided for free.
Accurate detection of 7 IDH1 and 5 IDH2 mutations using PCR clamping
Sensitive identification of 3 mutations using ARMS PCR technology
A standardized assay with ready-to-use solutions
An easy workflow with the Rotor-Gene Q instrument
Genetron Health has the most advanced detection platform, comprehensive and diverse, can quickly and accurately according to clinical samples of various types of nucleic acid and protein detection, provide strong support for cancer genomics research and clinical application: two generation sequencing (NGS), generation sequencing (Sanger) and digital PCR (dPCR), fluorescence quantitative PCR (qPCR), pyrosequencing (Pyrose-quencing), fluorescence capillary electrophoresis, fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Equipment including Novoseq 6000，HiSeq X Ten，HiSeq 4000，MiSeq，NextSeq， QuantStudio，RainDance，PyroMark, etc..